Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;140(5):709-724.
doi: 10.1007/s00439-020-02221-8. Epub 2020 Sep 13.

The role of the gut microbiome in graft fibrosis after pediatric liver transplantation

Affiliations
Review

The role of the gut microbiome in graft fibrosis after pediatric liver transplantation

Tian Qin et al. Hum Genet. 2021 May.

Abstract

Liver transplantation (LT) is a life-saving option for children with end-stage liver disease. However, about 50% of patients develop graft fibrosis in 1 year after LT, with normal liver function. Graft fibrosis may progress to cirrhosis, resulting in graft dysfunction and ultimately the need for re-transplantation. Previous studies have identified various risk factors for the post-LT fibrogenesis, however, to date, neither of the factors seems to fully explain the cause of graft fibrosis. Recently, evidence has accumulated on the important role of the gut microbiome in outcomes after solid organ transplantation. As an altered microbiome is present in pediatric patients with end-stage liver diseases, we hypothesize that the persisting alterations in microbial composition or function contribute to the development of graft fibrosis, for example by bacteria translocation due to increased intestinal permeability, imbalanced bile acids metabolism, and/or decreased production of short-chain fatty acids (SCFAs). Subsequently, an immune response can be activated in the graft, together with the stimulation of fibrogenesis. Here we review current knowledge about the potential mechanisms by which alterations in microbial composition or function may lead to graft fibrosis in pediatric LT and we provide prospective views on the efficacy of gut microbiome manipulation as a therapeutic target to alleviate the graft fibrosis and to improve long-term survival after LT.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Possible mechanisms of persistent dysbiosis in liver fibrosis. DAMP damage-associated molecular pattern, ECM extracellular matrix, FXR farnesoid X receptor, PAMP pathogen-associated molecular pattern, SCFA short-chain fatty acid, TGFβ transforming growth factor β, TLR toll-like receptor
Fig. 2
Fig. 2
Translocation of PAMPs due to higher intestinal permeability. Alteration of the intestinal microbiome, caused by liver diseases, administration of antibiotics or potential post-LT complications, is hypothesized to contribute to the graft fibrogenesis. Thus, the altered microbial composition/function leads to increased intestinal permeability and translocation of bacteria along with PAMPs to liver via the portal vein. Translocated PAMPs activate TLRs on hepatic Kupffer cells to induce the proinflammatory pathways, further resulting in the activation of HSCs. HSCs produce the ECM and initiate the liver fibrogenesis. ECM, extracellular matrix, HSC hepatic stellate cell, PAMP pathogen-associated molecular pattern, TLR toll-like receptor
Fig. 3
Fig. 3
Experimental framework to understand the role of microbial composition/function on the development of graft fibrosis post LT. a Hypothesis that altered gut microbial composition/function contributes to the development of graft fibrosis in pediatric LT; b Experimental framework containing three objectives to systematically evaluate various aspects of the hypothesized role of the gut microbiome on graft fibrosis after pediatric LT. FMT fecal microbiota transplant, LT liver transplantation, PAMP pathogen-associated molecular pattern; SCFA short-chain fatty acid

References

    1. Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020;72:558–577. doi: 10.1016/j.jhep.2019.10.003. - DOI - PubMed
    1. Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, Reali L, Anania F, Nobili V. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276–1285. doi: 10.1111/apt.12758. - DOI - PMC - PubMed
    1. Annavajhala MK, Gomez-Simmonds A, Macesic N, Sullivan SB, Kress A, Khan SD, Giddins MJ, Stump S, Kim GI, Narain R, Verna EC, Uhlemann AC. Colonizing multidrug-resistant bacteria and the longitudinal evolution of the intestinal microbiome after liver transplantation. Nat Commun. 2019;10:4715. doi: 10.1038/s41467-019-12633-4. - DOI - PMC - PubMed
    1. Ardalan M, Vahed SZ. Gut microbiota and renal transplant outcome. Biomed Pharmacother. 2017;90:229–236. doi: 10.1016/j.biopha.2017.02.114. - DOI - PubMed
    1. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ, Rudensky AY. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504:451–455. doi: 10.1038/nature12726. - DOI - PMC - PubMed

Substances